CLINICAL TRIAL STATUS REPORT
Protocol SENT-2025-001: AI-Assisted Diagnostic System Validation
Classification: HIPAA PROTECTED - PHI REDACTED
Document Date: November 2025

================================================================================
STUDY OVERVIEW
================================================================================

Protocol Number: SENT-2025-001
Study Title: Validation of AI-Assisted Diagnostic Platform for Early Cancer Detection
Trial Phase: Phase III Pivotal Trial
ClinicalTrials.gov ID: NCT05234567

Principal Investigator: Dr. Amanda Chen, MD, PhD
Safety Officer: Dr. James Wilson, MD
Biostatistician: Dr. Maria Rodriguez, PhD
Sponsor: SENTINEL Medical Division

================================================================================
ENROLLMENT SUMMARY
================================================================================

Target Enrollment: 500 patients
Patients Enrolled: 487 patients
Patients Completed Treatment: 412 patients
Patients Currently Active: 52 patients
Patients Withdrawn: 23 patients (4.7% dropout rate)

Enrollment by Site:
- Site 001 (University Medical Center): 156 patients
- Site 002 (Regional Cancer Center): 134 patients
- Site 003 (Academic Medical Center): 112 patients
- Site 004 (Community Hospital): 85 patients

================================================================================
PRIMARY ENDPOINT RESULTS
================================================================================

PRIMARY ENDPOINT: Improvement in Early Detection Rate

Target Improvement: 20% increase in early-stage detection
Achieved Improvement: 25% improvement in early detection rate

Statistical Analysis:
- p-value: <0.001
- Confidence Interval (95%): 22.3% - 27.8%
- Statistical Significance: ACHIEVED

Primary Endpoint Status: MET - Study achieved primary objective

SECONDARY ENDPOINTS:

1. Sensitivity: 94.2% (Target: >90%) - MET
2. Specificity: 91.8% (Target: >85%) - MET
3. False Positive Rate: 8.2% (Target: <15%) - MET
4. Time to Diagnosis: Reduced by 47% (Target: >30%) - EXCEEDED

================================================================================
SAFETY DATA
================================================================================

ADVERSE EVENTS REPORTED:

Serious Adverse Events (SAEs): 12 events (2.5% of patients)
- Related to study procedure: 2 events
- Unrelated (underlying condition): 10 events
- Deaths: 3 (all unrelated to study - underlying cancer progression)

Common Adverse Events:
1. Anxiety related to screening: 67 patients (13.8%)
2. Minor discomfort during imaging: 34 patients (7.0%)
3. Allergic reaction to contrast (mild): 8 patients (1.6%)

Safety Assessment: ACCEPTABLE SAFETY PROFILE
No safety signals identified requiring study modification.

================================================================================
DATA CLASSIFICATION
================================================================================

Data Classification: HIPAA Protected Health Information
De-identification: All PHI removed per HIPAA Safe Harbor method
IRB Approval: Protocol approved by Central IRB (IRB-2024-0892)
Data Monitoring: Independent Data Safety Monitoring Board (DSMB) oversight

================================================================================
REGULATORY STATUS
================================================================================

FDA Communications:
- Pre-submission meeting: Completed March 2024
- Breakthrough Device Designation: Granted May 2024
- 510(k) Submission: Planned Q1 2026

Current Phase: Data lock and statistical analysis
Database Lock Date: October 31, 2025

================================================================================
PUBLICATION TIMELINE
================================================================================

Manuscript Preparation:
- Primary Analysis Manuscript: In preparation
- Target Journal: New England Journal of Medicine (NEJM)
- Planned Submission: Q1 2026
- Conference Presentation: ASCO 2026 Annual Meeting (abstract submitted)

================================================================================
KEY PERSONNEL
================================================================================

Principal Investigator: Dr. Amanda Chen, MD, PhD
Co-Investigators:
- Dr. Michael Park, MD (Radiology)
- Dr. Sarah Thompson, MD (Oncology)
- Dr. Robert Lee, PhD (Biomedical Engineering)

Safety Officer: Dr. James Wilson, MD
Study Coordinator: Jennifer Martinez, RN, BSN
Data Manager: Thomas Brown, MS

================================================================================
DOCUMENT METADATA
================================================================================
Document ID: MED-CT-2025-001
Author: Dr. Amanda Chen, Principal Investigator
Classification: HIPAA Protected
IRB Protocol: SENT-2025-001
Review Date: November 30, 2025
